Abstract: The present invention relates to a process for preparation of Batefenterol of Formula (I) or pharmaceutically acceptable salts thereof, and the process for the preparation of the chiral intermediate compounds including compound of Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds of Formula (VII), followed by preparation of Batefenterol from the intermediate compounds of Formula (VII) via intermediate compounds of Formula (X) and Formula (XI); or via intermediate compounds of Formula (IX) and Formula (XI); or via intermediate compounds of Formula (VII) and Formula (XI); or via intermediate compounds of the Formula (XV) and Formula (XVI); or via intermediate compounds of the Formula (XIX) and Formula (XVI). The process is cost effective and gives higher yield and better purity.

Abstract: The present invention relates to a process for preparation of Navafenterol of Formula (I) and intermediate compounds of Formula (VII) and Formula (XIII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds of Formula (VII) and Formula (XIII) followed by preparation of Navafenterol from the compound of Formula (XIII) either by condensation with the compound of Formula (XVI); or via intermediates of the compound of Formula (XVIII) and compound of Formula (XV); or via intermediates of the compound of Formula (XI-a) and compound of Formula (XVI). The process uses simple raw materials and reagents. Further, the process is cost effective and gives higher yield and better purity.

Abstract: The present invention relates to a process for preparation of Abediterol of the Formula (I) or its pharmaceutically acceptable salts, and intermediate compounds including the compound of the Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds followed by preparation of Abediterol from the intermediate compounds. The compound Abediterol having the formula I is synthesized by various routes from the intermediate compound of Formula (VII). The process is cost effective and gives higher yield and better purity. The process of the present invention uses simple raw materials and reagents; and does not use hypertoxic materials.

Abstract: Disclosed is a process for preparing ?-agonist, 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino) ethanol, of Formula I. The process comprises refluxing 1-(4-amino-3,5-dichlorophenyl) ethanone of Formula II and selenium dioxide in the presence of 1,4-dioxane to form compound of Formula III. Further, compound of Formula III is heated at a temperature below 30° C. in the presence of t-butyl amine to form compound of Formula IV. The compound of Formula IV is treated with sodium borohydride to form compound of Formula I.

Abstract: The present invention relates to a process for preparing indacaterol or salts thereof. The process comprises of forming compound of Formula 1 by reacting compound of Formula 2 and compound of Formula 3 in the presence of a solvent to Form compound of Formula 4, which on removal of the protecting groups forms compound of Formula 1.

Abstract: The present invention relates to a process for preparing olodaterol and intermediates thereof. The process comprises of forming compound of Formula 1 by reacting compound of Formula 2 or its acid salt with compound of Formula 3 in the presence of an organic solvent to obtain compound of Formula 4. Protecting groups are removed from compound of Formula 4 in the presence of a suitable solvent to form compound of Formula 1.

Abstract: There is provided a process for preparation of sitagliptin of Formula II or a pharmaceutically acceptable salt thereof by deprotection of Formula IX.

Abstract: There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

Abstract: There is provided an improved process for the preparation of Sitagliptin of Formula II by reduction of compound of Formula VIII to Formula IX followed by deprotection of Formula IX to afford Sitagliptin of Formula II.

Abstract: There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

Abstract: Processes for the preparation of prasugrel and its pharmaceutically acceptable salts thereof. Also disclosed are polymorphic forms of prasugrel hydrochloride and processes for their preparation.

Abstract: A process for preparing valsartan.

Abstract: A process for preparing irbesartan comprises pentanoylation of cycloleucine in the presence of sodium hydroxide to form n-pentanoyl cycloleucine, condensing this product with 2-(4-aminomethyl phenyl) benzonitrile using dicyclohexyl carbodiimide and 1-hydroxy benzotriazole as a catalyst to form the 4-(&quest-N-pentanoyl amino) cyclopentamido methyl-2?-cyano biphenyl compound, and then cyclizing using trifluoroacetic acid in the presence of an aromatic solvent to form cyano irbesartan. Cyano irbesartan is converted to irbesartan by reaction with tributyltin chloride and sodium azide in the presence of an aromatic solvent.

Abstract: Co-crystals comprising aripiprazole and fumaric acid.

Abstract: Processes for preparing paliperidone.

Abstract: A process for preparing amorphous montelukast sodium comprises removing solvent from a solution comprising montelukast sodium using agitated thin film drying.

Abstract: The current invention is concerned with methods and compositions for the removal of arsenic contamination from water. A method for binding As to oxidized metal coated pumice and method for making the same are disclosed. Water filters comprising oxidized metal coated pumice, such as oxidized iron coated pumice, are also provided.

Abstract: An apparatus for the photocatalyitc oxidation of common industrial effluent contaminants in aqueous solution includes a reactor and a thin film photocatalyst fixed to a support material like Cuddapah stone. The support material is preferably an inert material. The TiO2 preformed does not contain any adsorbent for making the thin film photocatalyst, The catalytic runs were carried out over TiO2 thin film fixed bed reactor. The study is extended to the immobilization of preformed TiO2 with a binder for making thin film using a simple spray technique on inert Cuddapah stone. This method of immobilization require no thermal treatment of the catalyst at high temperatures. The method is applicable for the photocatalytic treatment of industrial effluents at a higher scale. Also it is a method for preparing a photocatalyst adopted for the oxidation of industrial common effluent by simple spray technique.